Press Releases

    Print Page  Close Window
BioMed Realty Trust Announces 36,900 Square Foot Lease in Seattle With Novo Nordisk

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR) today announced the signing of a new lease at its 530 Fairview Avenue property in Seattle, Washington. A wholly owned subsidiary of Novo Nordisk A/S, a healthcare company and world leader in diabetes care, has agreed to lease 36,900 square feet, anchoring BioMed's recently constructed research facility in Seattle's South Lake Union market.

Commenting on the project, Don Foster, Corporate Vice President of Novo Nordisk, said, "530 Fairview Avenue is an excellent facility that provides us with all of the critical infrastructure that we need to effectively pursue our research, and the South Lake Union market is a tremendous location that enables us to recruit key scientists to help us pursue our goals."

Alan Gold, BioMed's President and Chief Executive Officer, commented, "We are thrilled to forge this new relationship with one of the world's premier healthcare companies. Novo Nordisk's commitment at our 530 Fairview Avenue property is a testament to the strength of South Lake Union -- a critical cluster for the region's preeminent research institutions -- and to BioMed's development team for producing another world-class facility that meets the rigorous requirements of the leading scientific research companies."

About Novo Nordisk

Novo Nordisk A/S is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as hemophilia management, growth hormone therapy and autoimmune inflammation therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information about Novo Nordisk, please visit http://www.novonordisk.com.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.9 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMed Realty Trust, Inc.